Fluoxetina Salipax

Quick links

Choose a section

Quick links to important sections

Advertisements

Fluoxetina Salipax

Advertisements
Advertisements

Overview of Fluoxetina Salipax

Quick Facts

Property Description
Active ingredient Fluoxetine hydrochloride
Form Capsule, Tablet, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Antidysphoric agent, managing mood imbalances
Origin Synthetic compound

What is Fluoxetina Salipax?

Fluoxetina Salipax: Classification and Identity

Fluoxetina Salipax is a prescription-only medicinal product classified as an antidepressant, belonging specifically to the group known as Selective Serotonin Reuptake Inhibitors (SSRIs). This classification establishes the medicine as a specialized psycholeptic designed to affect the central nervous system. The product contains the active substance Fluoxetine and is intended solely for systemic use via the oral route, commonly supplied as a capsule, tablet, or oral solution. Fluoxetine is internationally recognized as a second-generation antidepressant, a classification supported by pharmacological studies demonstrating its high selectivity for the serotonergic system.

Composition, Origin, and Purpose of Fluoxetine

The core composition is the active ingredient, Fluoxetine hydrochloride, which is a synthetic compound manufactured through controlled chemical processes. This compound functions as an SSRI, implying its main mechanism is the selective blocking of the reabsorption of the neurotransmitter serotonin in the brain. This mechanism increases the concentration of serotonin, a process clinically recognized for its role in regulating mood, cognition, and emotional stability. The general therapeutic purpose of this action is to act as an antidysphoric agent, helping to establish a more stable emotional baseline for individuals experiencing persistent mood imbalances. While Fluoxetina Salipax is a specific trade name, its core active ingredient, Fluoxetine, is globally known and frequently prescribed across adult and specific pediatric patient groups for its established effectiveness in regulating mood.

Regulatory References

  1. Fluoxetine: MedlinePlus Drug Information
  2. Fluoxetine - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Fluoxetina Salipax?

Possible side effects and safety information

Fluoxetina Salipax, containing fluoxetine, is associated with a range of possible adverse reactions that are officially documented in government regulatory sources. These effects are classified according to frequency and impact on physiological systems.

Adverse Reaction Classification

Very Common side effects, which may affect more than 1 in 10 patients, include Headache, Insomnia, Nausea, Diarrhea, and Somnolence (drowsiness). Reactions classified as Common often affect the Gastrointestinal system (e.g., Dry Mouth, Anorexia), the Nervous System (e.g., Tremor, Anxiety, Nervousness), and Sexual Function (e.g., decreased libido, abnormal ejaculation).

System-Organ Class Examples of Documented Effects
Psychiatric Disorders Insomnia, Abnormal Dreams, Anxiety, Libido Decreased
Nervous System Disorders Headache, Tremor, Somnolence, Dizziness
Gastrointestinal Disorders Nausea, Diarrhea, Dry Mouth, Dyspepsia
General Disorders Asthenia (Weakness), Sweating, Fatigue

Serious Safety Characteristics

Official labeling highlights several serious safety characteristics. The potential for an increased risk of suicidal thoughts and behaviors is noted, particularly in children, adolescents, and young adults during initial treatment or dose changes. Other documented serious reactions include the potential for Serotonin Syndrome, Activation of Mania/Hypomania, and, in rare instances, QT Prolongation and associated ventricular arrhythmias.

Population and Regulatory Safety Notes

Safety considerations are officially defined for specific patient populations. Older Adults have a noted increased susceptibility to Hyponatremia (low sodium levels). Patients with Hepatic Impairment may require reduced or less frequent administration due to prolonged clearance. The risk of suicidal thoughts and behaviors may emerge early after treatment initiation. Furthermore, the medicine is restricted from use concomitantly with non-selective, irreversible Monoamine Oxidase Inhibitors (MAOIs).

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that a suspected overdose of fluoxetine hydrochloride (Fluoxetina Salipax) is a medical emergency requiring immediate professional attention due to the potential for severe, documented systemic effects.

Documented Overdose Manifestations

Regulatory sources describe common clinical presentations, including nausea, vomiting, somnolence (drowsiness), and tremor, often accompanied by tachycardia (rapid heart rate).

Severe Outcomes and Risks

More critically, the official labeling warns of life-threatening events that may occur. These severe outcomes include the potential for seizures and Serotonin Syndrome (or NMS-like reactions). A major documented concern is cardiotoxicity, specifically QT prolongation on the ECG, which can lead to severe cardiac events such as ventricular arrhythmia and Torsades de Pointes. Fatal outcomes have been reported in human overdose experience, particularly when co-ingested with other substances. Individuals with pre-existing cardiac risk factors are subject to specific caution in these scenarios.

Required Emergency Actions

Regulatory guidance mandates that immediate medical attention be sought for any suspected overdose. The required clinical management is symptomatic and supportive treatment, as no specific antidote is known. Emergency procedures officially described include maintaining the airway and continuous monitoring of vital signs and the ECG due to the risk of delayed-onset cardiotoxicity. The presence of any severe symptom requires immediate contact with emergency services.

Advertisements

Therapeutic Uses of Fluoxetina Salipax

Fluoxetine Salipax is a medication whose therapeutic action supports the management of several psychiatric and mood-related conditions. As a prescription treatment, its therapeutic action is centered on helping manage the symptoms associated with these conditions.

The medication is approved for treating several conditions. Its main uses include the acute and maintenance management of Major Depressive Disorder (MDD), where it is indicated for symptoms such as persistent sadness and loss of interest. It is also approved for Obsessive Compulsive Disorder (OCD) and Panic Disorder (with or without agoraphobia).

Additionally, it is a treatment for the eating disorder Bulimia Nervosa and, in combination with olanzapine, is used for acute depressive episodes associated with Bipolar I Disorder and for Treatment Resistant Depression. This range of approved uses means the drug may be part of a comprehensive strategy to address diverse mood and behavioral patterns.

Quick Fact: Indicated for managing symptoms associated with Persistent Sadness

Advertisements

Eligibility and Restrictions for Use

This information summarizes the official regulatory guidelines for who can and cannot use fluoxetine (Salipax), strictly based on governmental documentation.

Population Eligibility Status Requirements/Restrictions
Absolutely Contraindicated Individuals with known hypersensitivity to fluoxetine or any component. Use is prohibited with a Monoamine Oxidase Inhibitor (MAOI), Pimozide, Thioridazine, Linezolid, or intravenous Methylene Blue.
Pediatric Use Approved for Major Depressive Disorder (MDD) in patients 8 years and older and for Obsessive-Compulsive Disorder (OCD) in patients 7 years and older. Safety and effectiveness are not established below these age limits.
Restricted/Conditional Use Patients with hepatic impairment require a lower or less frequent dosage. Caution is necessary for patients with a history of seizures, angle-closure glaucoma, or conditions predisposing to QT prolongation (cardiac risk factors). Screening for Bipolar Disorder is mandated before starting treatment.
Pregnancy and Lactation Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended due to the excretion of the drug and its active metabolite into breast milk.
Advertisements

What should I know about interactions with other medicines?

The interaction profile for Fluoxetina Salipax is defined by its metabolic activity and its effects on the central nervous system. All interaction information is derived from official government regulatory documents.

Interaction Restrictions and Contraindications

The co-administration of Fluoxetina Salipax is strictly prohibited (contraindicated) with several medicinal products due to the risk of serious adverse events. This includes all Monoamine Oxidase Inhibitors (MAOIs), such as linezolid and intravenous methylene blue. A mandatory washout period of at least 14 days is required when discontinuing an MAOI before starting Fluoxetina Salipax, and at least 5 weeks must elapse after stopping Fluoxetina Salipax before initiating an MAOI. The combination with Pimozide and Thioridazine is also contraindicated due to the documented risk of QTc interval prolongation. Thioridazine must not be used within 5 weeks of discontinuing fluoxetine.

Pharmacokinetic and Pharmacodynamic Interactions

Fluoxetina Salipax is classified as a potent inhibitor of the metabolic enzyme CYP2D6. This pharmacokinetic interaction can increase the systemic exposure of co-administered medicines that are primarily metabolized by this pathway, such as certain Tricyclic Antidepressants and Antiarrhythmics. Pharmacodynamic interactions include the risk of Serotonin Syndrome when combined with other serotonergic agents (e.g., Triptans, Lithium, Tramadol, and St. John's Wort). Additionally, co-administration with agents that interfere with hemostasis, such as NSAIDs or Warfarin, may potentiate the risk of bleeding. For individuals with hepatic impairment, slower clearance may increase systemic exposure, which can heighten interaction risks. Food does not affect the drug's bioavailability, but alcohol use should be avoided.

Advertisements

Mechanism of Action

Primary Mechanism: Selective Serotonin Reuptake Inhibition

Fluoxetina Salipax operates primarily as a selective serotonin reuptake inhibitor (SSRI). Its fundamental biological target is the serotonin transporter (SERT) protein, located on the presynaptic neuronal membrane. By blocking the reabsorption (reuptake) of the neurotransmitter serotonin (5-HT) from the synaptic cleft, the drug rapidly increases the extracellular concentration of 5-HT available to stimulate postsynaptic receptors. This initial action initiates pathway modulation within specific neural circuits.


Adaptive Neuroplasticity and Pathway Modulation

Sustained elevation of synaptic serotonin triggers a downstream mechanistic cascade involving long-term adaptive changes. This includes the desensitization of presynaptic 5-HT autoreceptors and the modulation of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF). This process supports the functional reorganization of neural pathways over time. Furthermore, the active metabolite, norfluoxetine, which also inhibits SERT, supports continuous pathway modulation due to its prolonged half-life, influencing activity patterns in central pathways.

Advertisements

Dosage and Administration Information

Administration Principles and Scheduling

Fluoxetina Salipax, which contains fluoxetine, is strictly administered via the oral route for systemic use. The medicine is provided in several dosage forms, including immediate-release capsules, tablets, an oral solution, and a delayed-release 90 mg capsule intended for once-weekly administration.

For most uses, the standard administration schedule is once daily, and the medication may be taken with or without food. Initial doses for conditions like Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) typically commence at 20 mg daily in adults.

Dosing Adjustment and Special Conditions

The dosage regimen is highly structured, defining an upper limit for administration; for instance, the maximum dose for MDD is limited to 80 mg per day. Specific administration instructions include the use of a calibrated measuring device when dispensing the oral solution, rather than a standard household spoon.

Guidelines also outline necessary adjustments for specific patient groups: a lower or less frequent dose is instructed for individuals with documented hepatic impairment (reduced liver function), sometimes requiring administration every second day. If a daily dose is missed, instructions state to skip the missed dose if it is near the time for the next scheduled dose, rather than taking a double amount. Furthermore, treatment duration is often prolonged; for example, documentation specifies continuing use for at least six months to maintain a symptom-free state in MDD.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluoxetina Salipax


Evidence for use in Depressive Episodes

Research has explored how Fluoxetina Salipax, as an active ingredient, was studied for symptoms associated with major depressive episodes. These studies monitored outcomes related to daily functioning and symptom intensity. Findings describe patterns observed where differences in outcomes were measured between individuals receiving the medication and those receiving a placebo (an inactive substance). The research highlights changes measured during short-term study periods, which contribute to understanding symptom patterns. Study results reflect the specific conditions under which they were conducted; research does not determine whether an individual will respond similarly. What remains uncertain is the full understanding of long-term symptom course and individual variability in response. Comparative evidence is still being developed, and data for certain patient subgroups remain insufficient.


Evidence for use in Obsessive-Compulsive Disorder (OCD)

Fluoxetina Salipax was studied for its use in individuals with Obsessive-Compulsive Disorder (OCD), a condition involving periods of heightened symptoms. Research has explored the potential for changes in outcomes capturing phases of heightened symptom activity. Studies focusing on episodes where symptoms become more noticeable explored whether Fluoxetina Salipax was associated with observed changes in the intensity of these symptoms in some people. While research provides insight into short-term changes, evidence is limited regarding the differences in response among various types of OCD presentations. Follow-up durations were limited in many initial trials.


Evidence for use in Bulimia Nervosa

Fluoxetina Salipax was evaluated in studies for its role in the context of Bulimia Nervosa, a condition associated with acute episodes of binge eating and purging. Research examined outcomes related to systemic or functional imbalance, specifically looking at the frequency of these behaviors in observed populations. The data show patterns related to observed change in the frequency of binge eating and purging episodes associated with Fluoxetina Salipax compared to placebo. Long-term effects on the overall course of the condition, including outcomes reflecting daily functioning over many years, are not fully established.


Evidence in Special Populations

Research has explored the use of this medication in children and adolescents with depressive episodes or OCD, and in older adults. The available evidence in children and adolescents was derived from trials assessing short-term symptom patterns. Subgroup findings are uncertain. Data for certain groups, such as those with comorbid conditions, remain insufficient. Research exploring patterns related to the use of this medication during pregnancy-related populations is an area where evidence is limited, and specific research is ongoing.


What is still uncertain about Fluoxetina Salipax

This section clarifies the areas where research is still needed or where findings have been mixed. The main evidence gaps include scenarios where comparative evidence is lacking against other treatments. Certainty remains low for certain less-common outcomes, as sample sizes were modest in some subgroup analyses. The main uncertainty lies in predicting how any single person will respond, as findings describe group patterns, not personal outcomes. Potential long-term changes are not fully established for everyone.

Key Studies & References Fluoxetine - StatPearls (for general indications, dosing, and special populations overview)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fluoxetina Salipax (FAQ)


Q: How long does it typically take to feel the effects of Fluoxetina Salipax?

According to official product information, it may take an individual four to five weeks, or even longer, to feel the full therapeutic benefit of the medication. Regulatory instructions often emphasize continuing treatment as directed by a healthcare provider, even if the effects are not immediately noticeable.


Q: What are the most common side effects people experience when starting Fluoxetina Salipax?

Regulatory documents list several effects that may affect more than 1 in 10 patients (very common). These include headache, difficulty sleeping (insomnia), nausea, diarrhea, and drowsiness (somnolence). These side effects are frequently reviewed in clinical settings, particularly at the beginning of therapy.


Q: Is it normal to feel more anxious when first starting this medication?

Anxiety and nervousness are listed in official product information as potential side effects. These symptoms may emerge or become noticeable during treatment, particularly when first starting therapy or following a change in dosage. Official warnings suggest that the emergence of such symptoms requires monitoring.


Q: How long do doctors usually recommend staying on Fluoxetina Salipax treatment?

For conditions such as Major Depressive Disorder (MDD), official documentation specifies that treatment should often continue for at least six months. This duration is recommended to help maintain a symptom-free state after initial improvement.


Q: What is the impact of Fluoxetina Salipax on sexual function?

Official information indicates that fluoxetine can affect sexual function. Common effects reported in regulatory documents include a decreased sex drive (libido) and abnormal ejaculation. Other sexual difficulties, such as delayed or absent orgasm, have also been reported.


Q: What are the signs of a serious or rare side effect from Fluoxetina Salipax?

Serious adverse events like Serotonin Syndrome have specific symptoms detailed in official warnings. These signs may include agitation, fever, excessive sweating, confusion, rapid or irregular heartbeat, or severe muscle stiffness. Patients experiencing concerning or unusual changes in behavior are advised in official warnings to seek guidance from their healthcare professional.


Q: How does Fluoxetina Salipax affect the brain's serotonin levels?

The medication is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Its core function is to block the reabsorption (reuptake) of the neurotransmitter serotonin in the brain. This action increases the concentration of serotonin available to stimulate nerve receptors, influencing pathways related to mood regulation.


Q: Why is Fluoxetina Salipax prescribed for anxiety?

Fluoxetine is approved by regulatory bodies for specific conditions that involve anxiety, such as panic disorder and Obsessive-Compulsive Disorder (OCD). These uses are based on clinical evidence; however, the authoritative regulatory texts focus on specific diagnoses and do not list Generalized Anxiety Disorder as a primary indication.


Q: Does Fluoxetina Salipax cause weight gain or loss?

Official product labeling lists altered appetite and changes in weight as potential warnings. Clinical trials have reported significant weight loss in some individuals. However, the long-term changes in weight can vary from person to person.


Q: Can Fluoxetina Salipax affect sleep patterns?

Yes, official side effect listings confirm that fluoxetine can affect sleep. Both difficulty sleeping (insomnia) and excessive drowsiness (somnolence) are reported as very common side effects. The medication may affect both the quality and duration of sleep.


Q: Do children and adolescents use Fluoxetina Salipax for depression?

Regulatory approvals permit the use of this medication for Major Depressive Disorder in patients who are 8 years old and above. It is also approved for Obsessive-Compulsive Disorder (OCD) in patients 7 years old and above.


Q: Can Fluoxetina Salipax cause strange dreams or nightmares?

Official side effect information lists 'Abnormal Dreams' as a common adverse reaction to the medication. This category includes experiences of strange or vivid dreams and may also encompass nightmares.


Q: Is Fluoxetina Salipax a medication that requires long-term commitment?

The medication is indicated for both short-term acute treatment and longer-term maintenance treatment for various conditions, such as Major Depressive Disorder (MDD). Maintenance therapy is often prolonged to ensure sustained stability.


Q: Why do some people feel agitated after starting Fluoxetina Salipax?

Official warnings note that agitation is a symptom that has been reported in patients taking antidepressants. This may occur particularly during the initial months of therapy or when the dose is adjusted. Official warnings recommend careful monitoring for agitation and other unusual behavioral changes, particularly early in treatment.


Q: Is it okay to drive while taking Fluoxetina Salipax?

Official warnings state that fluoxetine has the potential to impair motor skills, judgment, and thinking. Regulatory documents advise patients to use caution when performing activities, such as driving or operating machinery, until they are certain the medication does not adversely affect their ability to perform such tasks.


Q: What is the typical timeframe for maximum therapeutic effect of Fluoxetina Salipax?

Regulatory references indicate that it may take four to five weeks or longer for an individual to experience the full therapeutic benefit of the medication. The initial effects are generally followed by the maximum benefit over this period.


Q: What are the main withdrawal symptoms associated with stopping Fluoxetina Salipax?

If the medication is stopped suddenly, regulatory sources note that symptoms may include mood changes, irritability, anxiety, dizziness, numbness or tingling sensations, and difficulty sleeping. These symptoms are part of what is known as discontinuation syndrome.


Q: What is the function of the specific inactive ingredients in Salipax?

The inactive ingredients are substances used in the manufacturing process and formulation of the drug to provide structure, bulk, color, and stability. Examples listed in official descriptions include starch, gelatin, titanium dioxide, iron oxide, and in the oral solution, flavoring agents and preservatives.


Q: Can Fluoxetina Salipax be taken with thyroid medication?

Regulatory case reports suggest that the addition of thyroid hormone supplementation may potentially enhance the therapeutic effect of fluoxetine in the treatment of major depression. Official documentation suggests that any co-administration requires assessment and close monitoring by a qualified healthcare provider.


Q: Is it possible for Fluoxetina Salipax to worsen depression initially?

Official warnings state that patients with Major Depressive Disorder (MDD) may experience a worsening of their depression, or suicidal thoughts, especially during the initial months of treatment or following a change in dose. This risk is why close monitoring is required, especially during the initial phase of therapy.


Q: Do I need to change my diet or lifestyle when taking Fluoxetina Salipax?

Official product information emphasizes that alcohol consumption should be avoided while taking this medication. Additionally, caution is advised when participating in activities that require complete mental alertness until its effects on the individual are established.


Q: What is the recommended approach for discontinuing Fluoxetina Salipax?

Official regulatory protocols generally recommend that when the medication is to be stopped, the dose should be reduced gradually. This process is typically carried out over a period defined by a healthcare provider to help minimize the risk of discontinuation symptoms.

Advertisements

How should Fluoxetina Salipax be stored and disposed of?

How to Store and Dispose of Fluoxetine (Fluoxetina Salipax)

Official regulatory guidelines define specific conditions to maintain the stability and safety of fluoxetine. The medication must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F), with protection from light required.

Storage Requirements

  • Temperature: Store within the 20 C to 25 C range; do not expose to temperatures outside 15 C to 30 C.
  • Protection: Keep the container tightly closed and store in the original container to protect it from light.
  • Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Fluoxetine must be disposed of according to local regulations. Regulatory authorities advise against discarding the medicine in wastewater or general household trash to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluoxetina Salipax found in:

A-Z Index: